334 related articles for article (PubMed ID: 34096329)
1. Comparison of Sinonasal Histopathological Changes in Biological Treatment of Eosinophilic Chronic Rhinosinusitis.
Ho J; Alvarado R; Rimmer J; Sewell WA; Walter S; Earls P; Campbell RG; Sacks R; Kalish LH; Harvey RJ
Am J Rhinol Allergy; 2022 Jan; 36(1):72-80. PubMed ID: 34096329
[TBL] [Abstract][Full Text] [Related]
2. Role of eosinophilic chronic rhinosinusitis in switching to benralizumab treatment in mepolizumab responders.
Hamada S; Kobayashi Y; Yasuba H
Int J Clin Pharmacol Ther; 2020 Dec; 58(12):703-708. PubMed ID: 32831163
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
4. Mepolizumab decreases tissue eosinophils while increasing type-2 cytokines in eosinophilic chronic rhinosinusitis.
Walter S; Ho J; Alvarado R; Smith G; Croucher DR; Liang S; Grayson JW; Mangussi-Gomes J; Van Es SL; Earls P; Rimmer J; Campbell R; Kalish L; Sacks R; Harvey RJ
Clin Exp Allergy; 2022 Dec; 52(12):1403-1413. PubMed ID: 35475305
[TBL] [Abstract][Full Text] [Related]
5. Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report.
Kagoshima H; Hori R; Kojima T; Okanoue Y; Taguchi A; Yamamoto H; Hasebe K; Shoji K
Respir Med Case Rep; 2020; 30():101135. PubMed ID: 32612919
[TBL] [Abstract][Full Text] [Related]
6. The roles of IL-5 and anti-IL-5 treatment in eosinophilic diseases: Asthma, eosinophilic granulomatosis with polyangiitis, and eosinophilic chronic rhinosinusitis.
Nagase H; Ueki S; Fujieda S
Allergol Int; 2020 Apr; 69(2):178-186. PubMed ID: 32139163
[TBL] [Abstract][Full Text] [Related]
7. IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.
Shimizu H; Hayashi M; Kato H; Nakagawa M; Imaizumi K; Okazawa M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681869
[TBL] [Abstract][Full Text] [Related]
8. [A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].
Matsumoto-Sasaki M; Shimizu K; Suzuki M; Suzuki M; Nakamaru Y; Konno S
Arerugi; 2020; 69(8):678-682. PubMed ID: 32963191
[TBL] [Abstract][Full Text] [Related]
9. Targeting the IL-5 pathway in eosinophilic asthma: a comparison of mepolizumab to benralizumab in the reduction of peripheral eosinophil counts.
Ghassemian A; Park JJ; Tsoulis MW; Kim H
Allergy Asthma Clin Immunol; 2021 Jan; 17(1):3. PubMed ID: 33407869
[TBL] [Abstract][Full Text] [Related]
10. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
Takabayashi T; Asaka D; Okamoto Y; Himi T; Haruna S; Yoshida N; Kondo K; Yoshikawa M; Sakuma Y; Shibata K; Suzuki M; Kobayashi M; Kawata R; Tsuzuki K; Okano M; Higaki T; Takeno S; Kodama S; Yonekura S; Saito H; Nozaki A; Otori N; Fujieda S
Am J Rhinol Allergy; 2021 Nov; 35(6):861-870. PubMed ID: 33840229
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
12. Anti-IL-5 therapies for chronic obstructive pulmonary disease.
Donovan T; Milan SJ; Wang R; Banchoff E; Bradley P; Crossingham I
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013432. PubMed ID: 33295032
[TBL] [Abstract][Full Text] [Related]
13. Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.
Hillas G; Fouka E; Papaioannou AI
Expert Rev Respir Med; 2020 Apr; 14(4):353-365. PubMed ID: 31958239
[No Abstract] [Full Text] [Related]
14. Systemic Predictors of Eosinophilic Chronic Rhinosinusitis.
Ho J; Hamizan AW; Alvarado R; Rimmer J; Sewell WA; Harvey RJ
Am J Rhinol Allergy; 2018 Jul; 32(4):252-257. PubMed ID: 29862828
[TBL] [Abstract][Full Text] [Related]
15. Benralizumab and mepolizumab treatment outcomes in two severe asthma clinics.
Langton D; Politis J; Collyer T; Khung SW; Bardin P
Respirology; 2023 Dec; 28(12):1117-1125. PubMed ID: 37638723
[TBL] [Abstract][Full Text] [Related]
16. Benralizumab in Patients with Severe Eosinophilic Asthma: A Multicentre Real-Life Experience.
Scioscia G; Tondo P; Nolasco S; Pelaia C; Carpagnano GE; Caiaffa MF; Valenti G; Maglio A; Papia F; Triggiani M; Crimi N; Pelaia G; Vatrella A; Foschino Barbaro MP; Crimi C
J Clin Med; 2023 Jun; 12(13):. PubMed ID: 37445397
[TBL] [Abstract][Full Text] [Related]
17. Safety of Eosinophil-Depleting Therapy for Severe, Eosinophilic Asthma: Focus on Benralizumab.
Jackson DJ; Korn S; Mathur SK; Barker P; Meka VG; Martin UJ; Zangrilli JG
Drug Saf; 2020 May; 43(5):409-425. PubMed ID: 32242310
[TBL] [Abstract][Full Text] [Related]
18. Long-Term Real-World Outcomes of Mepolizumab and Benralizumab Among Biologic-Naive Patients With Severe Eosinophilic Asthma: Experience of 3 Years' Therapy.
Fyles F; Nuttall A; Joplin H; Burhan H
J Allergy Clin Immunol Pract; 2023 Sep; 11(9):2715-2723. PubMed ID: 37245734
[TBL] [Abstract][Full Text] [Related]
19. [Clinical and economic comparison of utilization of reslizumab, mepolizumab and benralizumab in the treatment of severe eosinophilic asthma].
Zyryanov SK; Avdeev SN; Ivanov DA; Zhuravleva MV; Kniajeskaia NP; Matveev NV; Nenasheva NA; Fomina DS; Frolov MI
Ter Arkh; 2020 Dec; 92(12):172-179. PubMed ID: 33720591
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: A Bayesian network meta-analysis.
Akenroye A; Lassiter G; Jackson JW; Keet C; Segal J; Alexander GC; Hong H
J Allergy Clin Immunol; 2022 Nov; 150(5):1097-1105.e12. PubMed ID: 35772597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]